Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
| Country | United States |
|---|---|
| Deadline | Not published |
| Published | 2026-11-05 |
| Sectors | Health & life sciences |
| Source | Grants.gov (US) |
Summary
Funding opportunity RFA-DK-28-113. CFDA: 93.KRP, 93.855
The buyer, the value, the full description and the link to the official notice are available with a free account.